NO306677B1 - Heterosykliske forbindelser, farmasöytiske preparater og anvendelse av en slik forbindelse til fremstilling av et medikament - Google Patents

Heterosykliske forbindelser, farmasöytiske preparater og anvendelse av en slik forbindelse til fremstilling av et medikament

Info

Publication number
NO306677B1
NO306677B1 NO953462A NO953462A NO306677B1 NO 306677 B1 NO306677 B1 NO 306677B1 NO 953462 A NO953462 A NO 953462A NO 953462 A NO953462 A NO 953462A NO 306677 B1 NO306677 B1 NO 306677B1
Authority
NO
Norway
Prior art keywords
drug
manufacture
compound
pharmaceutical preparations
heterocyclic compounds
Prior art date
Application number
NO953462A
Other languages
English (en)
Norwegian (no)
Other versions
NO953462L (no
NO953462D0 (no
Inventor
Per Sauerberg
Preben H Olesen
Charles Howard Mitch
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO953462D0 publication Critical patent/NO953462D0/no
Publication of NO953462L publication Critical patent/NO953462L/no
Publication of NO306677B1 publication Critical patent/NO306677B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO953462A 1993-03-05 1995-09-04 Heterosykliske forbindelser, farmasöytiske preparater og anvendelse av en slik forbindelse til fremstilling av et medikament NO306677B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/026,708 US5376668A (en) 1990-08-21 1993-03-05 Heterocyclic compounds
PCT/DK1994/000095 WO1994020495A1 (en) 1993-03-05 1994-03-04 Heterocyclic compounds and their preparation and use

Publications (3)

Publication Number Publication Date
NO953462D0 NO953462D0 (no) 1995-09-04
NO953462L NO953462L (no) 1995-11-03
NO306677B1 true NO306677B1 (no) 1999-12-06

Family

ID=21833368

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953462A NO306677B1 (no) 1993-03-05 1995-09-04 Heterosykliske forbindelser, farmasöytiske preparater og anvendelse av en slik forbindelse til fremstilling av et medikament

Country Status (12)

Country Link
US (7) US5376668A (zh)
EP (1) EP0687265B1 (zh)
JP (3) JPH08507298A (zh)
CN (1) CN1046721C (zh)
AT (1) ATE212345T1 (zh)
AU (1) AU695110B2 (zh)
CA (1) CA2157580A1 (zh)
DE (1) DE69429717T2 (zh)
FI (1) FI954131A0 (zh)
NO (1) NO306677B1 (zh)
NZ (1) NZ262374A (zh)
WO (1) WO1994020495A1 (zh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545638A (en) * 1993-12-21 1996-08-13 Novo Nordisk A/S Method of treating gastrointestinal motility disorders
IL112024A (en) * 1993-12-21 1999-07-14 Novo Nordisk As Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5672709A (en) * 1994-10-24 1997-09-30 Eli Lilly And Company Heterocyclic compounds and their preparation and use
DK0709094T3 (da) * 1994-10-31 2000-07-10 Lilly Co Eli Tetrahydropyridinoxadiazol- eller thiadiazolforbindelse til behandling af angst
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
JP2000501097A (ja) * 1995-11-29 2000-02-02 イーライ・リリー・アンド・カンパニー ヘテロ環式化合物およびそれらの使用
US5998434A (en) * 1995-12-06 1999-12-07 Eli Lilly And Company Composition for treating pain
EA199800535A1 (ru) * 1995-12-07 1998-12-24 Эли Лилли Энд Компани Способ лечения боли
EP0821957A3 (en) * 1996-08-01 1998-04-22 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating substance abuse
EP0821959A3 (en) * 1996-08-01 1998-09-16 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
PT821955E (pt) * 1996-08-01 2002-07-31 Lilly Co Eli Uso de 3-(4-hexiloxi-1,2,5-tiadiazol-3-il)-1,2,5,6-tetrahidro-1-metilpiridina (xanomelina) para o tratamento da doenca bipolar
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
EP0821958A3 (en) * 1996-08-01 1998-07-08 Eli Lilly And Company Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (xanomeline) for treating excessive aggression
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US6376675B2 (en) * 1999-01-22 2002-04-23 The University Of Toledo Muscarinic receptor agonists
US6239134B1 (en) 1999-03-03 2001-05-29 American Home Products Corp. Diazole derivatives as serotonergic agents
KR100351629B1 (ko) * 2000-08-29 2002-09-11 한국화학연구원 5-(4-치환된-[1,2,5]티아디아졸-3-일)-3-메틸-1,2,3,4-테트라하이드로피리미딘 유도체와 이의 제조방법
US20030212379A1 (en) * 2002-02-26 2003-11-13 Bylund Adam David Systems and methods for remotely controlling medication infusion and analyte monitoring
US20030212344A1 (en) * 2002-05-09 2003-11-13 Vadim Yuzhakov Physiological sample collection devices and methods of using the same
US7343188B2 (en) * 2002-05-09 2008-03-11 Lifescan, Inc. Devices and methods for accessing and analyzing physiological fluid
DE60333762D1 (de) * 2002-08-23 2010-09-23 Novartis Vaccines & Diagnostic Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
CA2511746C (en) 2003-11-06 2013-03-26 Lifescan, Inc. Drug delivery pen with event notification means
US6923498B1 (en) * 2003-11-18 2005-08-02 Brent Alan Mecham Recreational vehicle cover
DE102005021587A1 (de) * 2005-05-10 2006-11-16 BSH Bosch und Siemens Hausgeräte GmbH Kältegerät und Betriebsverfahren dafür
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009521531A (ja) * 2005-12-27 2009-06-04 ザ・ユニバーシティ・オブ・トレド ムスカリンアゴニスト及びその使用方法
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2296471A4 (en) 2008-05-15 2012-03-14 Univ Toledo MUSCARIC ACID AGONISTS AS COGNITIVE ENHANCERS
WO2012149524A1 (en) 2011-04-29 2012-11-01 The University Of Toledo Muscarinic agonists as enhancers of working memory and cognitive flexibility
WO2021097427A1 (en) * 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219646A (en) * 1986-03-27 1990-10-26 Merck Sharp & Dohme Oxadiazole derivatives of azacyclics for treating cns disorders
GB8610432D0 (en) * 1986-04-29 1986-06-04 Akzo Nv Amino-thiazole & oxazole derivatives
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
GB8717446D0 (en) * 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
IE63906B1 (en) * 1987-11-13 1995-06-14 Novo Nordisk As Azabicyclic compounds and their preparation and use
EP0322182A3 (en) * 1987-12-22 1992-01-02 Beecham Group Plc Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
DK162892C (da) * 1988-07-04 1992-05-11 Novo Nordisk As 1,2,5,6-tetrahydropyridinforbindelser, deres fremstilling og farmaceutiske praeparater indeholdende disse
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
EP0459568A3 (en) * 1990-05-31 1992-09-30 Merck Sharp & Dohme Ltd. Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma and novel compounds having such use
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
WO1992009280A1 (en) * 1990-11-29 1992-06-11 Allergan, Inc. Use of pyridine derivatives in the treatment of ocular hypertension

Also Published As

Publication number Publication date
JP2002302489A (ja) 2002-10-18
FI954131A (fi) 1995-09-04
NO953462L (no) 1995-11-03
JP2000309587A (ja) 2000-11-07
FI954131A0 (fi) 1995-09-04
USRE36375E (en) 1999-11-02
US5773452A (en) 1998-06-30
AU695110B2 (en) 1998-08-06
US5376668A (en) 1994-12-27
AU6202994A (en) 1994-09-26
US5571826A (en) 1996-11-05
US5919805A (en) 1999-07-06
CN1121717A (zh) 1996-05-01
JP3378556B2 (ja) 2003-02-17
CA2157580A1 (en) 1994-09-15
DE69429717T2 (de) 2002-08-14
CN1046721C (zh) 1999-11-24
EP0687265A1 (en) 1995-12-20
US5559136A (en) 1996-09-24
JPH08507298A (ja) 1996-08-06
DE69429717D1 (de) 2002-03-14
NO953462D0 (no) 1995-09-04
WO1994020495A1 (en) 1994-09-15
US5658932A (en) 1997-08-19
NZ262374A (en) 1997-06-24
EP0687265B1 (en) 2002-01-23
ATE212345T1 (de) 2002-02-15

Similar Documents

Publication Publication Date Title
NO306677B1 (no) Heterosykliske forbindelser, farmasöytiske preparater og anvendelse av en slik forbindelse til fremstilling av et medikament
KR960701049A (ko) 헤테로사이클릭 화합물, 이의 제조방법 및 이의 용도(Heterocyclic compounds and their preparation and use)
DK198390D0 (da) Heterocykliske forbindelser, deres fremstilling og anvendelse
ATE174027T1 (de) Heterozyklische verbindungen, ihre herstellung und anwendung
DK0544714T3 (da) Heterocycliske forbindelser og fremstilling og anvendelse deraf
NO302523B1 (no) Heterosykliske forbindelser, farmasöytiske preparater som omfatter dem, og anvendelse av forbindelsene for fremstilling av medikamenter

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN SEPTEMBER 2003